PMID- 10226770
OWN - NLM
STAT- MEDLINE
DCOM- 19990720
LR  - 20191024
IS  - 0767-3981 (Print)
IS  - 0767-3981 (Linking)
VI  - 13
IP  - 2
DP  - 1999
TI  - Pentoxifylline decreases neutrophil respiratory bursts in patients with stable 
      angina.
PG  - 237-42
AB  - We estimated the effect of pentoxifylline (PTX) on the respiratory burst 
      (examined by chemiluminescence method) of unprimed and primed neutrophils with 
      tumor necrosis factor-alpha (TNF-alpha) in patients with stable angina pectoris. 
      Chemiluminescence of non-stimulated as well as 
      formyl-methionyl-leucyl-phenylalanine (fMLP) and phorbol myristate acetate (PMA) 
      stimulated neutrophils was measured. We studied 45 patients with stable angina 
      subjected to percutaneous transluminal coronary angioplasty (PTCA) procedure, who 
      were randomly divided into two groups. The study group consisted of 24 patients 
      who were administered pentoxifylline orally, and the control group consisted of 
      21 patients without pentoxifylline administration. Blood samples for examination 
      were collected from the coronary sinus and peripheral vein just before the PTCA 
      procedure. Pentoxifylline decreased the respiratory burst of non-stimulated and 
      fMLP-stimulated neutrophils without affecting the chemiluminescence of PMA 
      stimulated neutrophils. Moreover, pentoxifylline diminished the chemiluminescence 
      non-stimulated and stimulated by fMLP but not by PMA of TNF-alpha primed 
      neutrophils. We presume that administration of PTX in stable angina patients may 
      have a beneficial effect.
FAU - Kowalski, J
AU  - Kowalski J
AD  - Department of Lung Diseases, Military Medical University of Lodz, Poland.
FAU - Kosmider, M
AU  - Kosmider M
FAU - Pasnik, J
AU  - Pasnik J
FAU - Zeman, K
AU  - Zeman K
FAU - Baj, Z
AU  - Baj Z
FAU - Janiszewska-Drobinska, B
AU  - Janiszewska-Drobinska B
FAU - Czekalska, R
AU  - Czekalska R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 59880-97-6 (N-Formylmethionine Leucyl-Phenylalanine)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Adult
MH  - Angina Pectoris/*metabolism
MH  - Angioplasty, Balloon, Coronary
MH  - Depression, Chemical
MH  - Female
MH  - Humans
MH  - In Vitro Techniques
MH  - Luminescent Measurements
MH  - Male
MH  - Middle Aged
MH  - N-Formylmethionine Leucyl-Phenylalanine/pharmacology
MH  - Neutrophils/*drug effects/metabolism
MH  - Pentoxifylline/*pharmacology
MH  - Respiratory Burst/*drug effects
MH  - Tetradecanoylphorbol Acetate/pharmacology
MH  - Tumor Necrosis Factor-alpha/pharmacology
EDAT- 1999/05/05 00:00
MHDA- 1999/05/05 00:01
CRDT- 1999/05/05 00:00
PHST- 1999/05/05 00:00 [pubmed]
PHST- 1999/05/05 00:01 [medline]
PHST- 1999/05/05 00:00 [entrez]
AID - S0767398199800929 [pii]
AID - 10.1111/j.1472-8206.1999.tb00345.x [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 1999;13(2):237-42. doi: 
      10.1111/j.1472-8206.1999.tb00345.x.